Iperionx Limited (AU:IPX)
ASX:IPX
Want to see AU:IPX full AI Analyst Report?
Top Page
Iperionx Limited
(Sydney:IPX)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$5.00
▼(-19.09% Downside)
Action:Reiterated
Date:05/12/26
The score is held down primarily by weak financial performance—no revenue, widening losses, and heavy ongoing cash burn—despite a relatively supportive low-leverage balance sheet. Technicals are constructive with the stock trading above key moving averages, but momentum appears stretched. Valuation is difficult to assess due to negative earnings and no dividend yield data.
Positive Factors
Low leverage / strong balance sheet
Very low reported leverage provides durable financial flexibility versus peers, lowering refinancing risk while the business scales. A stronger equity base and larger asset base extend runway for commercialization investments and strategic partnerships without immediate debt pressure.
Negative Factors
Pre-revenue business profile
A multi-year pre-revenue status means the firm's core technology and commercialization remain unproven at scale; revenue timing is uncertain. This prolongs reliance on capital markets and increases execution risk versus peers that already monetize products in target end markets.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Very low reported leverage provides durable financial flexibility versus peers, lowering refinancing risk while the business scales. A stronger equity base and larger asset base extend runway for commercialization investments and strategic partnerships without immediate debt pressure.
Read all positive factors
Iperionx Limited (IPX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$1.85B
Dividend YieldN/A
Average Volume (3M)2.36M
Price to Earnings (P/E)―
Beta (1Y)3.60
Revenue GrowthN/A
EPS Growth-50.75%
CountryAU
Employees28
SectorBasic Materials
Sector Strength58
IndustryIndustrial Materials
Share Statistics
EPS (TTM)-0.17
Shares Outstanding339,384,060
10 Day Avg. Volume1,615,955
30 Day Avg. Volume2,359,717
Financial Highlights & Ratios
PEG Ratio-1.48
Price to Book (P/B)10.04
Price to Sales (P/S)0.00
P/FCF Ratio-23.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$8.25Price Target Upside33.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.16
Revenue Forecast (FY)AU$6.40M
Iperionx Limited Business Overview & Revenue Model
Company Description
IperionX Limited focuses on the development of low carbon titanium for space, aerospace, electric vehicles, and 3D printing industries. The company also produces titanium metal powders from titanium scrap at its operational pilot facility in Utah....
How the Company Makes Money
IperionX’s current and intended monetization is centered on commercializing titanium metal production and related products/services through a U.S.-based supply chain. Revenue (where generated) is expected to come primarily from (1) sales of titani...
Iperionx Limited Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
68
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -657.16K | -634.11K | -211.58K | -9.38K |
| EBITDA | -35.31M | -37.79M | -22.49M | -17.48M | -29.39M | -8.82M |
| Net Income | -35.43M | -35.35M | -22.23M | -25.93M | -21.52M | -14.43M |
Balance Sheet | ||||||
| Total Assets | 129.24M | 105.03M | 55.44M | 22.80M | 9.91M | 2.79M |
| Cash, Cash Equivalents and Short-Term Investments | 65.87M | 54.81M | 33.16M | 11.94M | 5.67M | 1.70M |
| Total Debt | 4.46M | 3.93M | 1.49M | 975.31K | 543.03K | 475.65K |
| Total Liabilities | 20.97M | 12.59M | 4.10M | 2.24M | 2.49M | 762.50K |
| Stockholders Equity | 108.27M | 92.44M | 51.34M | 20.56M | 7.42M | 1.76M |
Cash Flow | ||||||
| Free Cash Flow | -14.24M | -39.41M | -26.68M | -18.57M | -14.06M | -3.62M |
| Operating Cash Flow | -8.89M | -21.80M | -18.61M | -15.86M | -12.13M | -3.56M |
| Investing Cash Flow | -5.62M | -24.28M | -6.53M | -5.71M | -3.07M | 1.76M |
| Financing Cash Flow | 855.79K | 67.99M | 46.59M | 27.89M | 19.39M | 3.50M |
Iperionx Limited Technical Analysis
Positive
6.18
Price Trends
4.49
Positive
5.52
Negative
5.96
Negative
Market Momentum
0.17
Negative
55.11
Neutral
65.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IPX, the sentiment is Positive. The current price of 6.18 is above the 20-day moving average (MA) of 5.19, above the 50-day MA of 4.49, and above the 200-day MA of 5.96, indicating a neutral trend. The MACD of 0.17 indicates Negative momentum. The RSI at 55.11 is Neutral, neither overbought nor oversold. The STOCH value of 65.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IPX.
Iperionx Limited Risk Analysis
Iperionx Limited disclosed 51 risk factors in its most recent earnings report. Iperionx Limited reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Iperionx Limited Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
50 Neutral | AU$1.85B | -38.01 | -35.30% | ― | ― | -50.75% | |
48 Neutral | AU$164.17M | -16.97 | -12.55% | ― | ― | -133.33% | |
47 Neutral | AU$177.59M | -4.48 | -12.76% | ― | ― | 17.61% | |
43 Neutral | AU$262.92M | -13.51 | -26.32% | ― | ― | -6.36% | |
42 Neutral | AU$1.00B | -20.21 | -18.49% | ― | 467.60% | -21.48% | |
41 Neutral | AU$191.08M | -53.53 | -0.58% | 1.54% | -0.53% | -77.84% |
* Basic Materials Sector Average
AU:IPX
Iperionx Limited
5.32
1.63
44.17%
AU:AGE
Alligator Energy Ltd
0.04
<0.01
16.13%
AU:OMH
OM Holdings Ltd.
0.24
-0.06
-21.14%
AU:LOT
Lotus Resources Limited
0.63
-1.62
-72.12%
AU:CAY
Canyon Resources Limited
0.13
-0.12
-48.00%
AU:A4N
Alpha HPA Limited
0.69
-0.23
-25.00%
Iperionx Limited Corporate Events
IperionX Director Lorraine Martin Increases Stake Through ADS Purchase
May 1, 2026
IperionX Limited has disclosed a change in the equity holdings of director Lorraine M. Martin, reflecting a modest increase in her direct ownership of the company via American Depositary Shares. Martin purchased 155 ADSs on market on April 28, 202...
IperionX Director Todd Hannigan Increases Shareholding in On-Market Purchase
Apr 30, 2026
IperionX Limited has disclosed a change in director Todd Hannigan’s interests, showing he has increased his direct and indirect holdings in the company. Hannigan acquired 480,000 additional fully paid ordinary shares on market over April 28 ...
IperionX Reaffirms Mineral Resource Estimates and Issues Investor Cautions
Apr 27, 2026
IperionX Limited has released an updated company presentation outlining its exploration and mineral resource development activities, referencing prior mineral resource estimates first disclosed in 2021. The company confirms there is no new materia...
IperionX Sets April Investor Webinar for Company Update
Apr 27, 2026
IperionX Limited has scheduled an investor webinar to provide a company update, underscoring its efforts to engage more directly with shareholders across its dual listings in the U.S. and Australia. Founder and CEO Taso Arima will host the online ...
IperionX Reports Lapse of 400,000 Performance Rights
Apr 24, 2026
IperionX Limited has notified the market of a change in its issued capital following the lapse of certain performance rights. A total of 400,000 IPXAL performance rights ceased on April 23, 2026, after the specified conditions for converting these...
IperionX grants performance-based options and rights to director Hannigan
Apr 2, 2026
IperionX Limited has updated the market on changes to director Todd Hannigan’s interests, confirming the issue of new options and performance rights as part of his compensation package. The equity awards, which carry exercise prices of A$18....
IperionX Adjusts Capital Structure as Incentive Securities Lapse
Apr 2, 2026
IperionX Limited has notified the market of the cessation of certain equity-linked incentives in its capital structure. The company reported that 890,000 performance rights expiring in December 2028 and 159,333 restricted stock units have lapsed.T...
Iperionx Issues New Unquoted Options and Performance Rights as Long-Term Incentives
Apr 2, 2026
Iperionx Limited has notified the market of the issuance of new unquoted equity securities, comprising two classes of options and a class of performance rights, all expiring on 2 April 2031. The grant of these long-dated incentives, struck at prem...
IperionX CEO Anastasios Arima Ups Equity Stake via On‑Market Purchases
Mar 29, 2026
IperionX Limited has disclosed a change in the holdings of managing director Anastasios Arima, who increased his direct and indirect interests in the company through on‑market purchases. Arima acquired 467,000 additional ordinary shares on t...
IperionX Shareholders Approve Director Equity Incentives at General Meeting
Mar 19, 2026
IperionX Limited reported the outcomes of its March 19, 2026 General Meeting of shareholders, where all resolutions put forward were carried by poll. The meeting followed procedures under Australian corporate and listing rules, underscoring the co...
IperionX denies undisclosed news behind share slump, details U.S. grant funding
Mar 16, 2026
IperionX Limited has responded to an ASX price query following a sharp fall in its share price from A$6.93 on 12 March 2026 to an intraday low of A$4.58 on 16 March 2026. The company stated it is not aware of any undisclosed information that could...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.